Irena Royzman to Present Webinar on “Written Description in the Life Sciences after Amgen v. Sanofi“
Partner Irena Royzman will present a webinar for the Intellectual Property Owner's Association entitled, "Written Description in the Life Sciences after Amgen v. Sanofi."
Hatch-Waxman litigation with generic manufacturers has long been the focus of competition involving traditional small molecule drugs. The litigation between Amgen and Sanofi regarding large molecule next-generation cholesterol drugs, however, illustrates the new prominence of innovator vs. innovator litigation in the pharmaceutical industry. In these types of cases, the law of written description looms large because innovators might try to cover all possible drugs that focus on a biologic target while disclosing only a few examples of a possibly large genus.
To learn more, or to register, click here.